Effects of desmopressin on the sleep of children suffering from enuresis

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

To evaluate the effect of 1-desamino-8-D-Arginine Vasopressin (DDAVP) on sleep architecture and arousal reactions in children with primary monosymptomatic nocturnal enuresis (PME).

Who Took Part

By PubMed's age tags, the people studied were children and teenagers, both men and women.

A prospective, placebo-controlled, randomized, double-blind, cross-over study was performed on children suffering from bed-wetting.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

Some participants received a placebo instead of Vasopressin, giving a reference point.

In the crossover set-up each of the participants took both Vasopressin and the comparison in turn, acting as their own control.

After lifting the blinding, the PSGs were compared.

What Was Measured

Topics PubMed links to this paper include Antidiuretic Agents, Deamino Arginine Vasopressin, Nocturnal Enuresis, Polysomnography and Sleep.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.